Constipation
Conditions
Brief summary
This study intends to recruit 90-100 constipated participants aged 25-50 years, including an equal number of males and females, from the faculty and logistics staff of Capital Medical University. Participants will be randomly divided into an intervention group (55-60 individuals) and a control group (35-40 individuals). The intervention group will consume 250 mL of Mengniu Daily Fiber Oat Milk daily for 4 weeks, while the control group will not receive oat milk intervention. Both groups will maintain their original lifestyles, including diet, sleep, and exercise, throughout the study period. Baseline surveys, dietary surveys, blood and urine routine tests, blood biochemical indices, and intestinal flora detection will be conducted before and after the intervention. Defecation status will be recorded, and gastrointestinal symptoms will be assessed using a Gastrointestinal Symptom Rating Scale. Statistical analysis will be performed to determine the laxative efficacy of oat milk.
Interventions
DIETARY_SUPPLEMENToat milk
The intervention group will consume 250 mL of Mengniu Daily Fiber Oat Milk daily for 28 consecutive days
Sponsors
Capital Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
Clinical diagnosis of non-organic and habitual constipation; Reduced defecation frequency; Increased stool hardness; Fewer than 4 bowel movements per week;
Exclusion criteria
Inability to take food orally or inability to comply with the required intake of the test product; Known allergy to oats or related products; Unclear primary gastrointestinal complaints; Physical weakness that prevents participation in the trial; History of surgery within the past 30 days that may cause constipation； Recent constipation caused by severe organic gastrointestinal lesions (e.g., colon cancer, severe enteritis, intestinal obstruction, inflammatory bowel disease); Constipation accompanied by significant abdominal pain; Acute gastrointestinal diseases within the past 30 days; Severe systemic diseases involving the cardiovascular, hepatic, renal, or hematopoietic systems; Ongoing treatment for comorbid conditions that may interfere with study participation; Recent use of substances related to the tested function that may influence outcome measurements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Intestinal Flora Composition Assessed by Metagenomic Sequencing | Collect feces and evaluate at baseline and at the fourth week. | Fecal samples from a randomly selected subgroup (30 participants in the intervention group and 15 in the control group) will be collected before and after the intervention. Metagenomic sequencing will be used to evaluate changes in intestinal microbiota composition and functional gene pathways, including metabolism-, immunity-, and disease-related gene sets. This outcome explores potential mechanisms by which the intervention exerts laxative effects. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Gastrointestinal Symptoms Assessed by the Gastrointestinal Symptom Rating Scale | Participates will fill out the questionnaire at baseline, Week 2, and Week 4. | Gastrointestinal symptoms will be evaluated using the Gastrointestinal Symptom Rating Scale (GSRS, 15 items; score range: 1-7, with higher scores indicating more severe symptoms). Assessments will be conducted at baseline, Week 2, and Week 4. Symptoms include reflux, abdominal pain, indigestion, diarrhea, and constipation. |
Contacts
Primary ContactXiuwen Ren, PH.D.
Outcome results
None listed